HUP0102880A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
HUP0102880A3
HUP0102880A3 HU0102880A HUP0102880A HUP0102880A3 HU P0102880 A3 HUP0102880 A3 HU P0102880A3 HU 0102880 A HU0102880 A HU 0102880A HU P0102880 A HUP0102880 A HU P0102880A HU P0102880 A3 HUP0102880 A3 HU P0102880A3
Authority
HU
Hungary
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
HU0102880A
Other languages
Hungarian (hu)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0102880A2 publication Critical patent/HUP0102880A2/en
Publication of HUP0102880A3 publication Critical patent/HUP0102880A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HU0102880A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions HUP0102880A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (2)

Publication Number Publication Date
HUP0102880A2 HUP0102880A2 (en) 2002-06-29
HUP0102880A3 true HUP0102880A3 (en) 2002-11-28

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102880A HUP0102880A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291D0 (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020050257A (en) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Prevention of Plaque Rupture by ACAT Inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4606027B2 (en) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Carbamate compounds having piperazine bonds as HDAC inhibitors
JP4617449B2 (en) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド N-hydroxyamide derivative having antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CN1192140A (en) * 1995-08-04 1998-09-02 沃尼尔·朗伯公司 Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
KR20000011095A (en) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Nonphenyl sulfoneamide as inhibitor of matrix metalloproteinase
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
ID30030A (en) 2001-11-01
YU3501A (en) 2005-06-10
WO2000004892A3 (en) 2000-05-18
HRP20010055A2 (en) 2002-04-30
ZA200100294B (en) 2002-01-10
CZ2001126A3 (en) 2002-01-16
EA200100153A1 (en) 2001-08-27
CN1310629A (en) 2001-08-29
NO20010291L (en) 2001-01-18
AU4701799A (en) 2000-02-14
IS5809A (en) 2001-01-12
WO2000004892A2 (en) 2000-02-03
IL140982A0 (en) 2002-02-10
BR9912296A (en) 2001-04-17
KR20010083134A (en) 2001-08-31
EE200100046A (en) 2002-06-17
JP2002521328A (en) 2002-07-16
CA2335062A1 (en) 2000-02-03
PL346011A1 (en) 2002-01-14
SK502001A3 (en) 2002-06-04
TR200100205T2 (en) 2001-05-21
OA11584A (en) 2004-07-20
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (en) 2001-01-18
HUP0102880A2 (en) 2002-06-29
BG105162A (en) 2001-12-29
EP1098662A2 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
EP1100392A4 (en) Methods and devices for reducing the mineral content of vascular calcified lesions
AU3034300A (en) Substituted benzimidazoles and their use as parp inhibitors
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
AU2212299A (en) Compositions and methods for the treatment of tumor
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
IL140982A0 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
HK1041827B (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the same
IT1302811B1 (en) PROCEDURE AND RELATED APPARATUS FOR DIRECT REDUCTION OF IRON OXIDES
EP0964686A4 (en) Methods and compositions for preventing or retarding the development of atherosclerotic lesions
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
PL348029A1 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
IT1302813B1 (en) DEVICE FOR THE DIRECT REDUCTION OF IRON OXIDES AND RELATED PROCEDURE
EP1135141A4 (en) Phospholipase inhibitors for the treatment of cancer
GB2343629B (en) Treatment of cellulite
IL140963A0 (en) Coupling device and use of same